<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185015</url>
  </required_header>
  <id_info>
    <org_study_id>200101-500</org_study_id>
    <nct_id>NCT01185015</nct_id>
  </id_info>
  <brief_title>A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization</brief_title>
  <acronym>SIGMART</acronym>
  <official_title>A Clinical Trial to Assess the Efficacy of Sigmart in Patients With Recurrent Angina After Coronary Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <brief_summary>
    <textblock>
      The multi-centric, open label, single arm and self controlled study is planned to assess the&#xD;
      efficacy of orally administered Sigmart in subjects with recurrent angina after coronary&#xD;
      revascularization. The primary objective of this study is to demonstrate that orally&#xD;
      administered Sigmart can improve the major Exercise Tolerance Test (ETT) result in recurrent&#xD;
      angina subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to 1 mm ST-depression</measure>
    <time_frame>until day 28</time_frame>
    <description>It is defined as the exercise time to develop 1 mm ST-segment depression in the same identified leads</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise tolerance test parameters</measure>
    <time_frame>until day 28</time_frame>
    <description>Exercise Tolerance Test (ETT) parameters include:&#xD;
Total exercise time&#xD;
Time to onset of chest pain using ETT&#xD;
Maximum ST-depression&#xD;
SBP × HR (Pressure Rate Product)&#xD;
Metabolic Equivalents (METs)&#xD;
ETT grade and Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of nitroglycerine (NTG).</measure>
    <time_frame>until day 28</time_frame>
    <description>Weekly assessment of NTG consumption until visit 4 (day 28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>until day 28</time_frame>
    <description>The incidence of adverse events (especially the incidence of headache)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>until day 28</time_frame>
    <description>Compliance % ([total number of tablets taken divided by the total number of tablets to be taken] multiplied by 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of angina attacks per week</measure>
    <time_frame>until day 28</time_frame>
    <description>Weekly assessment of angina attacks until day 28</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Angina Pectoris</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sigmart (nicorandil)</intervention_name>
    <description>Sigmart will be administered for 2 weeks when the subject enters the secondary treatment period (Day 15 to approximately Day 28), at the dosage of 5 mg per oral tid in addition to the previous anti-anginal regimen.</description>
    <other_name>Sigmart®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects should be 18~70 years old, male or female&#xD;
&#xD;
          -  Subjects should have a history of coronary revascularization at least 6 months ago&#xD;
&#xD;
          -  Subjects should present with typical angina or similar to the chest pain before prior&#xD;
             coronary revascularization for at least 1 month&#xD;
&#xD;
          -  Subjects should be relieved from anginal attacks with short-acting NTG&#xD;
&#xD;
          -  Subjects should have the ability to withhold medication which cannot be concomitant in&#xD;
             this clinical study during the study&#xD;
&#xD;
          -  Subjects should have an ability to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Left main coronary artery disease&#xD;
&#xD;
          -  Aortic stenosis&#xD;
&#xD;
          -  Obstructive hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Subjects with hypertension (SBP&gt;170 mmHg or DBP&gt;100 mmHg) or hypotension (SBP&lt;90 mmHg&#xD;
             or DBP&lt;60 mmHg)&#xD;
&#xD;
          -  Postural hypotension (drop in systolic blood pressure &gt;20% after 2 minute standing),&#xD;
&#xD;
          -  Congestive heart failure (NYHA class III - IV)&#xD;
&#xD;
          -  Ejection fraction (EF)&lt;45% by Echocardiography&#xD;
&#xD;
          -  Peripheral arterial obstructive disease or other diseases limiting exercise testing&#xD;
&#xD;
          -  Arrhythmias requiring active treatment&#xD;
&#xD;
          -  Gastro-intestinal ulcer&#xD;
&#xD;
          -  Liver dysfunction (defined as ALT or bilirubin&gt;1.5×upper limit of normal value)&#xD;
&#xD;
          -  Significant renal impairment, such as serum creatinine greater than 1.5 folds the&#xD;
             upper limit of normal as determined by local clinical laboratory&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Concomitant medication such as Trimetazidine, Sulphonylurea, PDE-5 inhibitor such as&#xD;
             sildenafil, Chinese traditional medicine for treatment of angina pectoris&#xD;
&#xD;
          -  Known intolerance to nitrates&#xD;
&#xD;
          -  Known allergic to nicotinic acid&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Any other contraindications mentioned in the SPC&#xD;
&#xD;
          -  Participation in another clinical study within the last 3 months&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Any other subjects assessed by the investigator as being unsuitable for the present&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cherry Ma, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Merck Pharmaceutical Consulting Ltd., China</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <last_update_submitted>July 1, 2014</last_update_submitted>
  <last_update_submitted_qc>July 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <name_title>Cherry Ma</name_title>
    <organization>Beijing Merck Pharmaceutical Consulting LTD, an affiliate of Merck KGaA, Darmstadt, Germany.</organization>
  </responsible_party>
  <keyword>Angina Pectoris, Coronary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicorandil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

